Because it preferentially expands CD8 T cells and NK cells, diverse forms of IL-15 have been developed as immunotherapeutic agents to stimulate anti-tumor immune responses, and IL-15 has been explored in preclinical and clinical studies as a monotherapy and a combination treatment with other therapeutic interventions (17, 18, 28–30). This evidence concerns the gene CD8A and neoplasm.